Episode Details
Back to Episodes
Daily Roundup | J&J Bispecific Combo Cuts Myeloma Progression Risk 89%
Published 12 hours ago
Description
J&J's Tecvayli–Talvey combo cut the risk of myeloma progression or death by 89% in earlier-line disease. Plus an FDA panel endorses wellness peptides including BPC-157, AstraZeneca's camizestran clears Europe in breast cancer, Repligen buys BioLife for $1.5B, BeOne's $300M reshoring push amid Trump's 200% generic tariff threat, Scribe's $129M gene-editing IPO, and Ipsen's Bylvay biliary atresia readout ahead.
Visit us at thepharmacloseout.com.